ProCE Banner Activity

Oral Paclitaxel With P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer

Slideset Download
Conference Coverage
Oral paclitaxel significantly improved confirmed ORR with less neuropathy and more gastrointestinal toxicity vs IV paclitaxel in MBC.

Released: December 20, 2019

Expiration: December 18, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen